Comparison Study of MDX-010 (CTLA-4) Alone and Combined With DTIC in the Treatment of Metastatic Melanoma
Status:
Completed
Trial end date:
2004-02-01
Target enrollment:
Participant gender:
Summary
The objectives of this study are to determine the safety and activity profile of multiple
doses of MDX-010, and to determine the whether the addition of cytotoxic chemotherapy
(decarbazine [DTIC]) can augment the effects of MDX-010 in patients with chemotherapy naïve
metastatic melanoma with a tolerable toxicity profile.